Mixed connective tissue disease-an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA)

Sharp, 1971, Association of autoantibodies to different nuclear antigens with clinical patterns of rheumatic disease and responsiveness to therapy, J Clin Invest, 50, 350, 10.1172/JCI106502

Kay, 1952, An improved preparation of sodium desoxyribonucleate, J Amer Chem Soc, 74, 1724, 10.1021/ja01127a034

Lowry, 1951, Protein measurement with the Folin phenol reagent, J Biol Chem, 193, 265, 10.1016/S0021-9258(19)52451-6

Ceriotti, 1955, Determination of nucleic acids in animal tissues, J Biol Chem, 214, 59, 10.1016/S0021-9258(18)70943-5

Burton, 1956, A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid, Biochem J, 62, 315, 10.1042/bj0620315

Stavitsky, 1954, Micromethods for the study of proteins and antibodies. I. Procedure and general applications of hemagglutination and hemagglutinationinhibition reactions with tannic acid and proteintreated red blood cells, J Immun, 72, 360, 10.4049/jimmunol.72.5.360

Tan, 1967, Relationship of nuclear staining patterns with precipitating antibodies in systemic lupus erythematosus, J Lab Clin Med, 70, 800

Tan, 1966, An immunofluorescent study of the skin lesions in systemic lupus erythematosus, Arthritis Rheum, 9, 37, 10.1002/art.1780090105

Tan, 1966, Deoxyribonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus, J Clin Invest, 45, 1732, 10.1172/JCI105479

Tan, 1966, Characteristics of a soluble nuclear antigen precipitating with sera of patients with systemic lupus erythematosus, J Immun, 96, 464, 10.4049/jimmunol.96.3.464

Holman, 1959, The reaction of the lupus erythematosus (L.E.) cell factor with deoxyribonucieoprotein of the cell nucleus, J Clin Invest, 38, 2059, 10.1172/JCI103984

Kabat, 1961, Experimental Immunochemistry, 135

Petz, 1971, Serum and cerebral spinal fluid complement and serum autoantibodies in systemic lupus erythematosus, Medicine, 50, 259, 10.1097/00005792-197107000-00002

Mancini, 1965, Immunochemical quantitation of antigens by single radial immunodiffusion, Immunochemistry, 2, 235, 10.1016/0019-2791(65)90004-2

Rodnan, 1965, Progressive systemic sclerosis (diffuse scleroderma)

Tuffanelli, 1961, Systemic scleroderma, Arch Derm (Chicago), 84, 359, 10.1001/archderm.1961.01580150005001

Pearson, 1965, Polymyositis and dermatomyositis

Dowben, 1965, Polymyositis and other diseases resembling muscular dystrophy, Arch Intern Med (Chicago), 115, 584, 10.1001/archinte.1960.03860170066015

Harvey, 1954, Systemic lupus erythematosus: review of the literature and clinical analysis of 138 cases, Medicine, 33, 291, 10.1097/00005792-195412000-00001

Holman, 1965, Systemic lupus erythematosus

Schur, 1968, Immunologic factors and clinical activity in systemic lupus erythematosus, New Eng J Med, 278, 533, 10.1056/NEJM196803072781004

Friou, 1967, Antinuclear antibodies: diagnostic significance and methods, Arthritis Rheum, 10, 151, 10.1002/art.1780100210

Dubois, 1971, Progressive systemic sclerosis (PSS) and localized scleroderma (morphea) with positive LE cell test and unusual systemic manifestations compatible with systemic lupus erythematosus (SLE), Medicine, 50, 199, 10.1097/00005792-197105000-00003

D'Angelo, 1969, Pathologic observations in systemic sclerosis (scleroderma), Amer J Med, 46, 428, 10.1016/0002-9343(69)90044-8

Clark, 1971, Serologic alterations in scleroderma and sclerodermatomyositis, 46, 104

Sharp, 1969, A distinct rheumatic disease syndrome associated with antibody to a particular nuclear antigen and unusual responsiveness to corticosteroid therapy, Clin Res, 17, 359

Sharp, 1969, Specific antibody to the extractable nuclear antigen (ENA) in the mixed connective tissue disease syndrome, J Lab Clin Med, 74, 1010

Sharp, 1970, Relationship of antibodies to the extractable nuclear antigen (ENA) to disease activity in systemic lupus erythematosus (SLE) and the mixed connective tissue disease (MCTD), Clin Res, 18, 617

Holman, 1965, Partial purification and characterization of an extractible nuclear antigen which reacts with SLE sera, Ann N Y Acad Sci, 124, 800, 10.1111/j.1749-6632.1965.tb19002.x

Burnham, 1968, The immunofluorescent tumor imprint technic. III. The diagnostic and prognostic significance of the “speckle”-inducing antinuclear antibody, Amer J Clin Path, 50, 683, 10.1093/ajcp/50.6.683

Beck, 1961, Variations in the morphological patterns of “autoimmune” nuclear fluorescence, Lancet, 1, 1203, 10.1016/S0140-6736(61)91944-4

Lachmann, 1961, Correlation of antinuclear antibodies and nuclear staining patterns, Lancet, 2, 436, 10.1016/S0140-6736(61)92523-5

Paterson, 1963, Suppression of allergic encephalomyelitis in rats by means of anti-brain serum, J Exp Med, 117, 755, 10.1084/jem.117.5.755

Chutná, 1964, Prevention and suppression of experimental autoimmune aspermatogenesis in adult guinea pigs, Folia Biol (Praha), 10, 177

Sharp, 1970, Autoantibodies. Friend or foe?, Amer J Med Sci, 259, 365, 10.1097/00000441-197006000-00001

Talal, 1970, Immunologic and viral factors in the pathogenesis of systemic lupus erythematosus, Arthritis Rheum, 13, 887, 10.1002/art.1780130620

Morris, 1971, Modification of NZB/NZW nephritis by extractable nuclear antigen (ENA)

Hughes, 1971, The release of DNA into serum and synovial fluid, Arthritis Rheum, 14, 259, 10.1002/art.1780140211

Mattioli, 1971, Characterization of a soluble nuclear ribonucleoprotein antigen reactive with SLE sera